NEW YORK (GenomeWeb News) – BD Diagnostics, a segment of Becton Dickinson, today announced that the US Food and Drug Administration has cleared the BD Max MRSA molecular test for marketing in the US.

The assay runs on the fully automated BD Max System and was developed to rapidly identify patients with methicillin-resistant Staphylococcus aureus.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.